Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2008
10/28/2008US7442501 Associated with connective tissue diseases, progeroid disorders, and aging; methods for isolating such molecules; and the use of such molecules in human and veterinary practice
10/28/2008US7442394 Combined effects of nutrients on proliferation of stem cells
10/28/2008US7442388 For administered via inhalation, dispersibility and storage stability
10/28/2008US7442386 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
10/28/2008US7442376 Glycoprotein hormone compositions containing two β subunits
10/28/2008US7442375 Compositions of beta-defensin inducing agents
10/28/2008US7442372 Intrathecal administering of genetic engineered enzyme such as iduronidase; reduced storage of mucopolysaccharides
10/28/2008US7442371 Recombinant human albumin-erythropoietin fusion proteins with long-lasting biological effects
10/28/2008US7442370 Polymer conjugates of mutated neublastin
10/28/2008US7442308 Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process
10/28/2008CA2433765C Use of botulinum toxin for treatment of articular pathologies
10/28/2008CA2367003C Peptides useful in treating multiple sclerosis and a pharmaceutical composition comprising the same
10/28/2008CA2359027C S-nitrosothiols as agents for the treatment of circulatory dysfunctions
10/28/2008CA2335472C Processes to generate submicron particles of water-insoluble compounds
10/28/2008CA2304130C Novel fas ligand derivative
10/28/2008CA2235805C Anti-cancer agent
10/28/2008CA2225924C Recombinant mistletoe lectin
10/28/2008CA2170748C Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
10/28/2008CA2145302C Peptide proteinaceous drug nasal powder composition
10/27/2008CA2586748A1 Agents for prophylaxis or treatment of neurological diseases and conditions
10/27/2008CA2585247A1 Agents for prophylaxis or treatment of neurological related diseases and conditions
10/23/2008WO2008128169A1 Sparc and methods of use thereof
10/23/2008WO2008128093A1 Calcium flux as a pharmacoefficacy biomarker for inhibitors of histone deacetylase
10/23/2008WO2008128089A1 Use of substrates as pharmacological chaperones
10/23/2008WO2008128039A2 Cluster ion implantation for defect engineering
10/23/2008WO2008127996A1 Methods and compositions for contributing to the treatment of cancers
10/23/2008WO2008127975A2 Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
10/23/2008WO2008127973A1 Cd161 ligand, pilar, for modulating activation and proliferation of t cells
10/23/2008WO2008127936A2 Composite maillard-resole binders
10/23/2008WO2008127813A1 Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use
10/23/2008WO2008127777A1 A lactase formulation
10/23/2008WO2008127711A2 Interferons of rhesus and cynomolgus origin and uses thereof
10/23/2008WO2008127679A1 Lyophilized pharmaceutical compositions and methods of making and using same
10/23/2008WO2008127642A1 Myelin specific ige unencumbered by corresponding blocking antibodies as a causative factor in multiple sclerosis
10/23/2008WO2008127613A1 New pharmaceutical compositions
10/23/2008WO2008127605A1 Pharmaceutical compositions comprising calcitonin and an aromatase inhibitor
10/23/2008WO2008127508A2 Titania nanotubes prepared by anodization in chloride-containing electrolytes
10/23/2008WO2008127419A2 Compositions and methods to increase the effect of a neurotoxin treatment
10/23/2008WO2008127355A2 Chemorepulsion of cells
10/23/2008WO2008127285A2 Target peptides for ovarian cancer immunotherapy
10/23/2008WO2008127279A2 Methods for treating, preventing and diagnosing porcine ttv infection
10/23/2008WO2008127251A1 Reversible inhibition of pyramidal gap junction activity
10/23/2008WO2008127248A1 Gene defects and mutant alk kinase in human solid tumors
10/23/2008WO2008127199A1 Methods of controlling tumorigenesis and diagnosing the risk thereof
10/23/2008WO2008127138A1 Composition for decelerating the ageing in the organism and for extending the life time thereof and the use of said composition
10/23/2008WO2008127100A1 Means and methods for counteracting protein aggregation
10/23/2008WO2008126932A2 Epigenetical regulation of brain plasticity
10/23/2008WO2008126846A1 Antibacterial agent for vancomycin-resistant gram-positive bacterium
10/23/2008WO2008125872A1 Wif-1 for accelerating wound healing
10/23/2008WO2008125869A1 Secreted frizzled related protein 3 for use in the inhibition of scarring
10/23/2008WO2008125864A1 Sfrp3 for use in accelerating wound healing
10/23/2008WO2008125635A1 Anti-tumor drug, medicament, composition, and use thereof
10/23/2008WO2008125464A1 Compounds for the diagnosis of diseases associated with vcam expression
10/23/2008WO2008125366A2 Treatment of autoimmune diseases
10/23/2008WO2008124974A1 Use of human urinary kallidinogenase for manufacturing a medicament for the treatment and/or prevention of hypertension complicated by cerebral infarction
10/23/2008WO2008094875A3 Methods for treating bone loss and bone disease associated with chronic kidney disease
10/23/2008WO2008093060A3 Peptides and their use
10/23/2008WO2008093058A3 Peptides and their use
10/23/2008WO2008087186A3 Peptides for use in the treatment of obesity
10/23/2008WO2008086505A3 Methods of using il-31 to treat airway hyper-responsiveness and asthma
10/23/2008WO2008076981A3 Inhibitors of ll-37- mediated immune reactivity to self nucleic acids
10/23/2008WO2008073292A3 Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
10/23/2008WO2008070276A3 Isolation op osteoinductive proteins
10/23/2008WO2008067145A3 Self-assembling peptide amphiphiles
10/23/2008WO2008065372A3 Modified erythropoietin polypeptides and uses thereof for treatment
10/23/2008WO2008064306A3 Methods and compositions relating to islet cell neogenesis
10/23/2008WO2008063577A3 Phospholipase c zeta mediated oocyte activation
10/23/2008WO2008062296A3 Nop receptor agonists for the treatment of l-dopa induced dyskinesias
10/23/2008WO2008056346A3 Anti-angiogenic compounds
10/23/2008WO2008049053A3 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
10/23/2008WO2008045488A3 Treatment of inflammation, demyelination and neuronal/axonal loss
10/23/2008WO2008043102A8 Vasoactive intestinal polypeptide compositions
10/23/2008WO2008042686A3 Multifunctional carriers for the delivery of nucleic acids and methods of use thereof
10/23/2008WO2008024242A3 Use of cd83 in combination therapies
10/23/2008WO2008022015A3 Retro-inverso incretin analogues, and methods of use thereof
10/23/2008WO2008021871A3 Triazolyl acyclic hepatitis c serine protease inhibitors
10/23/2008WO2008011204A3 Self-assembling protein hydrogel with bio-active protein
10/23/2008WO2008005276A3 Growth factor delivery system containing antimicrobial agents
10/23/2008WO2007134245A3 Elastin-like polymer delivery vehicles
10/23/2008WO2007133812A3 Improved carriers for delivery of nucleic acid agents to cells and tissues
10/23/2008WO2007126653A3 Smooth muscle relaxation
10/23/2008WO2007109668A3 Compositions and methods for improving bone mass through modulation of novel receptors of pth and fragments thereof
10/23/2008WO2007092628A3 Methods and compositions for modulating conjunctival goblet cells
10/23/2008WO2007084737A3 Intraventricular enzyme delivery for lysosomal storage diseases
10/23/2008WO2007061631A3 Production of glycoproteins with reduced o-glycosylation
10/23/2008WO2007059190A3 Compositions of and methods of using stabilized psma dimers
10/23/2008WO2006121926A8 Neural regeneration peptides and methods for their use
10/23/2008WO2005115341A3 Microparticles for oral delivery
10/23/2008US20080263690 Neuregulin-1 transgenic mouse and methods of use
10/23/2008US20080263689 Screening/monitoring rate of internalization of insulin receptors in insulin-stimulated hepatocytes; identifying modulators of insulin clearance and secretion; treating insulin resistance
10/23/2008US20080262444 Percutaneously Absorbable Preparation, Percutaneously Absorbable Preparation Holding Sheet, and Percutaneously Absorbable Preparation Holding Equipment
10/23/2008US20080262415 topical administration of a biocompatible composition comprising a neurostimulatory and/or neuroprotective macrolide, and doxycycline or azithromycin, for a duration sufficient to enhance viability, confer protection, reduce scarring, degeneration of neural cells and/or stimulate sensation
10/23/2008US20080262411 treatment of obesity by electrical activation or deactivation of the nervous system, using electrodes, then further performing surgery and administering anorexigenic agents
10/23/2008US20080262199 Kit comprising inhibitory peptide for use in reducing side effects of drug cessation
10/23/2008US20080262013 Oxymorphone controlled release formulations
10/23/2008US20080261912 For treatment of endocrine-regulated tumors, for example, breast, prostate, ovarian and colon cancers
10/23/2008US20080261894 Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis
10/23/2008US20080261893 Contains neo-tryptophan; transdermal patches
10/23/2008US20080261892 Angiogenesis; neovascularization; lyophilization; kits
10/23/2008US20080261891 Compositions and methods for using syringopeptin 25a and rhamnolipids
1 ... 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 ... 3163